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A commentary on
Incorporation of membrane-anchored flagellin or Escherichia coli heat-labile enterotoxin B
subunit enhances the immunogenicity of rabies virus-like particles in mice and dogs
by Qi, Y. (2015). Front. Microbiol. 6:169. doi: 10.3389/fmicb.2015.00169
Rabies virus is accountable for substantial economic burden, and possesses high risk to the
individuals living in low-income countries. Rabies is fatal encephalitis caused by the rabies
virus (RABV) and usually transmit to humans through bites from rabid animals. The causative
agent for this life threatening disease is RABV, containing single-stranded negative-sense RNA
as genetic material (Jackson, 2013). Annually, rabies is responsible for approximately 55,000
deaths worldwide (a substantial part of deaths occur in developing countries); (Ge et al., 2011).
Vaccination is the principal path for prevention and control of the disease. Currently available
cell culture based rabies vaccines possess several side effects (e.g. fever, headache, neurological
disease etc.) and high cost in developing countries usually require many doses to provide pre
and post-exposure protection against the RABV. Several, improved vaccines based on anti-
rabies monoclonal antibodies, lyophilized, and cell culture technology, are already under clinical
development phase (Kaur et al., 2015). Furthermore, recombinant molecules have also been used as
vaccine candidates very extensively. Further, immunogenicity of these molecules can be enhanced
by combining adjuvants and immuno-stimulatory molecules. In the past, Wen et al. demonstrated
that recombinant rabies virus (rRABV) expressing dendritic cell activating molecules such as
granulocyte-macrophage colony stimulating factor (GM-CSF), macrophage-derived chemokine
(MDC), and macrophage inflammatory protein (MIP-1a), could enhance RABV immunogenicity
(Wen et al., 2011). Moreover, Zhou et al. suggested that rRABV expressing bacterial flagellin could
also induce robust adaptive immune responses (Zhou et al., 2013). Flagellin is a very effective and
potent adjuvant because of non-inducer of IgE production and at very low dose (1–10µg in non-
human primates) very efficient to induce effective immune responses (Mizel and Bates, 2010).
Recombinant virus-like particles (VLPs) are promising vaccine candidates, because they mimic
original virus structure and are able to induce potent humoral and cellular immune responses
(Kumar et al., 2011). Moreover, VLP possesses several advantages over the conventional vaccines
because of the lack of genetic material, stable in extreme environment and capable of expressing
foreignmolecules. Very recently, Fontana et al. (2014) showed that VLPs containing glycoprotein of
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RABV are very efficient in induction of antibody mediated
immune responses in Balb/c mice. Qi et al. (2015) combined
all these novel strategies, in order to develop an effective RABV
vaccine. In present report, Qi and colleagues constructed
chimeric RABV-like particles (cRVLPs) containing RABV
glycoprotein and matrix protein, expressing membrane-
anchored flagellin or E. coli heat-labile enterotoxin B (LTB).
Immunological studies in BALB/c mice and dog models
demonstrated that both humoral and cellular immune responses
were stronger with cRVLPs, compared with standard rabies
VLPs (sVLPs). Further, Qi et al. (2015) suggest that flagellin
promote antigen processing and presentation by inducing higher
expression of MHC I and II on the surface of DCs. Interestingly,
in a pioneer study, mucosal delivery of inactivated influenza
vaccine have been shown to induce heterotypic immunity against
H1N1 virus, when administered with heat-labile enterotoxin
B (Tumpey et al., 2001). These attributes make flagellin and
enterotoxin B outstanding adjuvants for use in vaccines.
In conclusion, present and previous reports suggest that
chimeric VLPs are novel class of subunit vaccines and possess
capability to induce both protective innate and adaptive immune
responses. Possibly, use of immuno-modulators along with
cRVLPS may enhance the efficacy of existing rabies vaccines.
Further, detailed mechanism of the comprehensive effect of
flagellin and enterotoxin B stimulated T and B-cells, on antiviral
immune responses, should be investigated.
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